Home > Oncology > Capivasertib may be helpful against tumors with rare AKT mutation

Capivasertib may be helpful against tumors with rare AKT mutation


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
JAMA Oncology
Reuters Health - 08/01/2021 - The protein kinase B/AKT inhibitor capivasertib shows a clinically significant objective response rate in patients with an AKT1 E17K-mutated metastatic tumor, according to a study targeting genetic tumor abnormalities, "As a field we are increasingly trying to move away from a one-size-fits-all approach when treating our patients with cancer," Dr. Kevin Kalinsky told Reuters Health by email. "In this National Cancer Institute-sponsored study, we identified that patients with previously treated metastatic cancer who have a rare mutation found in their tumor (AKT E17K mutation) can significantly respond when administering an oral drug that specifically targets that mutation." Of the more than 5,500 patients in the NCI-MATCH trial who had central testing of their tumor, only 68 patients (1.2%) had an AKT1 E17-mutated tumor, Dr. Kalinsky of the Winship Cancer Institute at Emory University, in Atlanta, and colleagues note in JAMA Oncology.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on